Great question — and it's worth clarifying that Attruby (acoramidis) is actually a stabilizer, not a "depleter." It works by stabilizing the transthyretin (TTR) protein so it doesn't misfold and form amyloid deposits in the heart. Think of it as putting a seatbelt on the protein to keep it from causing trouble.
Here's what Show Full Answer
Great question — and it's worth clarifying that Attruby (acoramidis) is actually a stabilizer, not a "depleter." It works by stabilizing the transthyretin (TTR) protein so it doesn't misfold and form amyloid deposits in the heart. Think of it as putting a seatbelt on the protein to keep it from causing trouble.
Here's what it does for the heart:
- Slows the buildup of amyloid deposits
- Reduces further stiffening of the heart walls
- Helps preserve heart function over time As for outlook at 71 with wild-type amyloidosis — there's genuinely encouraging news here.
Wild-type amyloidosis progresses slowly, which already gives it a more favorable outlook compared to other types. Key points for someone in your situation:
- Studies show around 52% of people on tafamidis (a similar stabilizer) were still alive after 5.5 years
- Nearly 80% of people diagnosed at 80 or older lived more than 18 months
- Early treatment, like being on Attruby now, is associated with much better outcomes
- One expert noted that people diagnosed early and treated promptly will likely "ultimately die of something else, not from this"
The factors that most influence outlook include overall heart health, certain blood biomarkers, and the ability to manage daily activities.
Being proactive and already on treatment at 71 puts things in a much better position. Keep that conversation going closely with your care team — they can track those biomarkers and adjust as needed. 💪
June 10
Join
Your Privacy Choices
